Impact of CD34 ⁺ cell infusion dose on immune reconstitution and survival in multiple myeloma after autologous stem cell transplantation

Autologous stem cell transplantation (ASCT) remains central in multiple myeloma, yet the optimal CD34⁺ infusion dose is uncertain. We retrospectively analyzed 176 newly diagnosed patients undergoing ASCT. Survival was estimated by Kaplan-Meier, and predictors were assessed by Cox regression. Among ASCT patients, a high CD34⁺ dose (≥5 × 10⁶/kg) was associated with superior progression-free survival (PFS, <i>p</i> = 0.020), OS (<i>p</i> < 0.001), deeper responses (<i>p</i> = 0.034), and sustained minimal residual disease (MRD) negativity (<i>p</i> = 0.001). High dose correlated with oligoclonal bands formation (OB, <i>p</i> = 0.038), indicating immune reconstitution. Patients exhibiting both high CD34⁺ dose and OB constituted the best OS (<i>p</i> < 0.001). In multivariate analysis, CD34⁺ ≥5 × 10⁶/kg independently predicted superior PFS (<i>p</i> = 0.014) and OS (<i>p</i> < 0.001). In sum, CD34⁺ ≥5 × 10⁶/kg is a practical dosing target that couples immune reconstitution <i>via</i> OB formation to durable post-ASCT survival, with no incremental benefit above 10.64 × 10⁶/kg.